Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Kintiroglou

Pediatrics West Orange, NJ Medical Doctor

NPI 1528198645 CMS profile 341021

1500 Pleasant Valley Way, Ste 306, West Orange, NJ 07052

Open in the dashboard

General payments

$2,262

133 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Kintiroglou of West Orange, NJ is reported in the CMS Open Payments database as having received $2,262 across 133 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $598 30
2024 General $316 20
2023 General $253 16
2022 General $590 30
2021 General $212 15
2020 General $169 13
2019 General $123 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Kintiroglou
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to John Kintiroglou were reported at $598. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year John Kintiroglou Pediatrics median Middle half National median
2019 $123 $86 $31–$183 $163
2020 $169 $49 $22–$110 $114
2021 $212 $68 $27–$158 $132
2022 $590 $77 $30–$173 $149
2023 $253 $88 $33–$190 $160
2024 $316 $94 $34–$206 $164
2025 $598 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $524 36 payments
  2. GlaxoSmithKline, LLC. $416 22 payments
  3. Pfizer Inc. $220 14 payments
  4. Baxter Healthcare $183 1 payment
  5. Sanofi Pasteur Inc. $177 9 payments
  6. Cranial Technologies, Inc $176 12 payments
  7. Supernus Pharmaceuticals, Inc. $82 6 payments
  8. Tris Pharma Inc $81 6 payments
  9. kaleo, Inc. $69 5 payments
  10. Neos Therapeutics, LP $62 4 payments
  11. Other $273 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,079 132 payments
  2. Long term medical supply or device loan $183 1 payment
Products named General payments · program years 2019–2025
  1. GARDASIL 9 $471 32 payments
  2. VAXELIS $350 24 payments
  3. VAXNEUVANCE $327 21 payments
  4. BEXSERO $283 19 payments
  5. ROTATEQ $183 13 payments
  6. Hillrom - OAE Hearing Screener $183 1 payment
  7. PEDIARIX $179 12 payments
  8. Doc Band $176 12 payments
  9. VAQTA $153 11 payments
  10. TRUMENBA $145 9 payments
  11. Other $1,743 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Pediatric Medicine: 38

Drug cost

$168

Median for Pediatric Medicine: $2,769

Branded share of claims

0%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levothyroxine Sodium Generic 13 $168

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AUVI-Q
  • kaleo, Inc. $30
$30 — —
BEXSERO
  • GlaxoSmithKline, LLC. $20
$20 — —
PEDIARIX
  • GlaxoSmithKline, LLC. $20
$20 — —
GARDASIL 9
  • Merck Sharp & Dohme Corporation $20
$20 — —
GARDASIL
  • Merck Sharp & Dohme Corporation $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

133 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record